Details of the Drug

General Information of Drug (ID: DMSQ8MD)

• Drug Name: Anagrelide
• Synonyms: Anagrelida; Anagrelidum; BL 416201; Agrylin (TN); Anagrelida [INN-Spanish]; Anagrelide [BAN:INN]; Anagrelide [INN:BAN]; Anagrelidum [INN-Latin]; Xagrid (TN); Anagrelide (INN/BAN); 6,7-Dichlor-1,5-dihydroimidazo(2,1-b)chinazolin-2(3H)-on; 6,7-Dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3H)-one; 6,7-dichloro-1,5-dihydroimidazo[2,1-]quinazolin-2(3H)-one; 6,7-dichloro-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one

Indication

Disease Entry	ICD 11	Status	REF
Thrombocythemia	3B63	Approved	[1]
Essential thrombocythemia	3B63.1Z	Phase 2	[2]

• Therapeutic Class: Antithrombotic Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 256.079
  Logarithm of the Partition Coefficient (xlogp); 1.6
  Rotatable Bond Count (rotbonds); 0
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 2
• ADMET Property:
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1 h [3]
  Bioavailability: The bioavailability of drug is 70% [3]
  Elimination: Less than 1% of drug is recovered in the urine as unchanged parent drug, while approximately 3% and 16-20% of the drug is recovered as 3-hydroxy anagrelide and RL603, respectively [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 1.5 hours [3]
  Metabolism: The drug is metabolized via the liver [3]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.55784 micromolar/kg/day [4]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Thalassaemia	Not Available	ABL1	OT09YVXH	[5]

• Chemical Identifiers:
  Formula: C10H7Cl2N3O
  IUPAC Name: 6,7-dichloro-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one
  Canonical SMILES: C1C2=C(C=CC(=C2Cl)Cl)N=C3N1CC(=O)N3
  InChI: InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16)
  InChIKey: OTBXOEAOVRKTNQ-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 135409400
  ChEBI ID: CHEBI:142290
  CAS Number: 68475-42-3
  DrugBank ID: DB00261
  TTD ID: D0D1HW
  INTEDE ID: DR0112
  ACDINA ID: D00038

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 3A (PDE3A)	TT06AWU	PDE3A_HUMAN	Inhibitor	[6]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 1A2 (CYP1A2) Main DME	DEJGDUW	CP1A2_HUMAN	Substrate	[7]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Tyrosine-protein kinase ABL1 (ABL1)	OT09YVXH	ABL1_HUMAN	Drug Response	[5]

Molecular Expression Atlas of This Drug

• ICD Disease Classification: 03 Disease of the blood or blood-forming organs
• Disease Class: ICD-11: 3B64 Thrombocytopenia
• The Studied Tissue: Whole blood
• The Studied Disease: Thrombocythemia [ICD-11:3B64]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Phosphodiesterase 3A (PDE3A)	DTT	PDE3A	3.33E-01	1.35E-02	0.14
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	6.75E-01	4.94E-02	4.06E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Anagrelide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Ivosidenib.	Acute myeloid leukaemia [2A60]	[8]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Midostaurin.	Acute myeloid leukaemia [2A60]	[9]
Idarubicin	DMM0XGL	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Idarubicin.	Acute myeloid leukaemia [2A60]	[9]
Daunorubicin	DMQUSBT	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Daunorubicin.	Acute myeloid leukaemia [2A60]	[9]
Arn-509	DMT81LZ	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Arn-509.	Acute myeloid leukaemia [2A60]	[9]
Gilteritinib	DMTI0ZO	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Gilteritinib.	Acute myeloid leukaemia [2A60]	[9]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Oliceridine.	Acute pain [MG31]	[9]
Terfenadine	DM4KLPT	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Terfenadine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[9]
Tacrine	DM51FY6	Moderate	Decreased metabolism of Anagrelide caused by Tacrine mediated inhibition of CYP450 enzyme.	Alzheimer disease [8A20]	[10]
Galantamine	DMEO794	Moderate	Increased risk of ventricular arrhythmias by the combination of Anagrelide and Galantamine.	Alzheimer disease [8A20]	[9]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Anagrelide and Rivastigmine.	Alzheimer disease [8A20]	[9]
Donepezil	DMIYG7Z	Moderate	Increased risk of ventricular arrhythmias by the combination of Anagrelide and Donepezil.	Alzheimer disease [8A20]	[9]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Anagrelide and Metronidazole.	Amoebiasis [1A36]	[10]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Anagrelide and Ivabradine.	Angina pectoris [BA40]	[11]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Bepridil.	Angina pectoris [BA40]	[9]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Dronedarone.	Angina pectoris [BA40]	[9]
Nifedipine	DMSVOZT	Moderate	Decreased metabolism of Anagrelide caused by Nifedipine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[10]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[9]
Alprazolam	DMC7XDN	Moderate	Decreased metabolism of Anagrelide caused by Alprazolam mediated inhibition of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[10]
Hydroxyzine	DMF8Y74	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[9]
Chlordiazepoxide	DMTN5XI	Moderate	Decreased metabolism of Anagrelide caused by Chlordiazepoxide mediated inhibition of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[10]
Promazine	DMZAL7W	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Promazine.	Appearance/behaviour symptom [MB23]	[9]
Voriconazole	DMAOL2S	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Voriconazole.	Aspergillosis [1F20]	[9]
Posaconazole	DMUL5EW	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Posaconazole.	Aspergillosis [1F20]	[9]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Anagrelide and Levalbuterol.	Asthma [CA23]	[12]
Terbutaline	DMD4381	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Terbutaline.	Asthma [CA23]	[13]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Anagrelide and Pirbuterol.	Asthma [CA23]	[13]
Salbutamol	DMN9CWF	Moderate	Increased risk of prolong QT interval by the combination of Anagrelide and Salbutamol.	Asthma [CA23]	[14]
Roflumilast	DMPGHY8	Moderate	Decreased metabolism of Anagrelide caused by Roflumilast mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[11]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Anagrelide and Formoterol.	Asthma [CA23]	[13]
Zileuton	DMVRIC2	Moderate	Decreased metabolism of Anagrelide caused by Zileuton mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[15]
Atomoxetine	DM5L6HI	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Atomoxetine.	Attention deficit hyperactivity disorder [6A05]	[9]
Lisdexamfetamine	DM6W8V5	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[9]
Desipramine	DMT2FDC	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[9]
Obeticholic acid	DM3Q1SM	Moderate	Decreased metabolism of Anagrelide caused by Obeticholic acid mediated inhibition of CYP450 enzyme.	Autoimmune liver disease [DB96]	[15]
Ofloxacin	DM0VQN3	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[9]
Ciprofloxacin XR	DM2NLS9	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[9]
Clarithromycin	DM4M1SG	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[9]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Anagrelide and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[9]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Gemifloxacin	DMHT34O	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[9]
Norfloxacin	DMIZ6W2	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[9]
Levofloxacin	DMS60RB	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[9]
Lomefloxacin	DMVRH9C	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[9]
Telithromycin	DMZ4P3A	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Telithromycin.	Bacterial infection [1A00-1C4Z]	[9]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Retigabine.	Behcet disease [4A62]	[9]
Loperamide	DMOJZQ9	Moderate	Increased risk of prolong QT interval by the combination of Anagrelide and Loperamide.	Bowel habit change [ME05]	[17]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Eribulin.	Breast cancer [2C60-2C6Y]	[9]
Lapatinib	DM3BH1Y	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Lapatinib.	Breast cancer [2C60-2C6Y]	[9]
Tamoxifen	DMLB0EZ	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Tamoxifen.	Breast cancer [2C60-2C6Y]	[9]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Toremifene.	Breast cancer [2C60-2C6Y]	[9]
Bosutinib	DMTI8YE	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Bosutinib.	Breast cancer [2C60-2C6Y]	[9]
Grepafloxacin	DMGLX0T	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Grepafloxacin.	Bronchitis [CA20]	[16]
Sotalol	DML60TN	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Sotalol.	Cardiac arrhythmia [BC9Z]	[9]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Anagrelide and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[9]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Anagrelide and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[13]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Anagrelide and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[12]
Salmeterol	DMIEU69	Moderate	Increased risk of prolong QT interval by the combination of Anagrelide and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[13]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Anagrelide and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[13]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Anagrelide and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[13]
Pentosan polysulfate	DM2HRKE	Moderate	Increased risk of bleeding by the combination of Anagrelide and Pentosan polysulfate.	Chronic pain [MG30]	[18]
Phenylbutazone	DMAYL0T	Moderate	Increased risk of bleeding by the combination of Anagrelide and Phenylbutazone.	Chronic pain [MG30]	[19]
Ketoprofen	DMRKXPT	Moderate	Increased risk of bleeding by the combination of Anagrelide and Ketoprofen.	Chronic pain [MG30]	[19]
Levomilnacipran	DMV26S8	Moderate	Increased risk of bleeding by the combination of Anagrelide and Levomilnacipran.	Chronic pain [MG30]	[20]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Anagrelide and Regorafenib.	Colorectal cancer [2B91]	[11]
Oxaliplatin	DMQNWRD	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Oxaliplatin.	Colorectal cancer [2B91]	[9]
Intedanib	DMSTA36	Moderate	Increased risk of bleeding by the combination of Anagrelide and Intedanib.	Colorectal cancer [2B91]	[21]
Isoproterenol	DMK7MEY	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Isoproterenol.	Conduction disorder [BC63]	[13]
Levobupivacaine	DM783CH	Moderate	Decreased metabolism of Anagrelide caused by Levobupivacaine mediated inhibition of CYP450 enzyme.	Corneal disease [9A76-9A78]	[11]
Halothane	DM80OZ5	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Halothane.	Corneal disease [9A76-9A78]	[9]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Anagrelide and Propofol.	Corneal disease [9A76-9A78]	[22]
Sevoflurane	DMC9O43	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Sevoflurane.	Corneal disease [9A76-9A78]	[9]
Lidocaine	DML4ZOT	Moderate	Decreased metabolism of Anagrelide caused by Lidocaine mediated inhibition of CYP450 enzyme.	Corneal disease [9A76-9A78]	[10]
Ropivacaine	DMSPJG2	Moderate	Decreased metabolism of Anagrelide caused by Ropivacaine mediated inhibition of CYP450 enzyme.	Corneal disease [9A76-9A78]	[10]
Probucol	DMVZQ2M	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Probucol.	Coronary atherosclerosis [BA80]	[9]
Ardeparin	DMYRX8B	Major	Increased risk of bleeding by the combination of Anagrelide and Ardeparin.	Coronary thrombosis [BA43]	[23]
Methadone	DMTW6IU	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Methadone.	Cough [MD12]	[9]
Clofazimine	DMEBOFW	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Clofazimine.	Crohn disease [DD70]	[9]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Mifepristone.	Cushing syndrome [5A70]	[9]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Pasireotide.	Cushing syndrome [5A70]	[9]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Osilodrostat.	Cushing syndrome [5A70]	[9]
Danaparoid	DM6CLBN	Major	Increased risk of bleeding by the combination of Anagrelide and Danaparoid.	Deep vein thrombosis [BD71]	[23]
Rivaroxaban	DMQMBZ1	Major	Increased risk of bleeding by the combination of Anagrelide and Rivaroxaban.	Deep vein thrombosis [BD71]	[24]
Sertraline	DM0FB1J	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Sertraline.	Depression [6A70-6A7Z]	[9]
Trimipramine	DM1SC8M	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Trimipramine.	Depression [6A70-6A7Z]	[9]
Fluoxetine	DM3PD2C	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Fluoxetine.	Depression [6A70-6A7Z]	[9]
Nortriptyline	DM4KDYJ	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Nortriptyline.	Depression [6A70-6A7Z]	[9]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Anagrelide and Vilazodone.	Depression [6A70-6A7Z]	[20]
Paroxetine	DM5PVQE	Moderate	Increased risk of bleeding by the combination of Anagrelide and Paroxetine.	Depression [6A70-6A7Z]	[20]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Anagrelide and Vortioxetine.	Depression [6A70-6A7Z]	[20]
Duloxetine	DM9BI7M	Moderate	Increased risk of bleeding by the combination of Anagrelide and Duloxetine.	Depression [6A70-6A7Z]	[20]
Milnacipran	DMBFE74	Moderate	Increased risk of bleeding by the combination of Anagrelide and Milnacipran.	Depression [6A70-6A7Z]	[20]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Escitalopram.	Depression [6A70-6A7Z]	[9]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of bleeding by the combination of Anagrelide and Desvenlafaxine.	Depression [6A70-6A7Z]	[20]
Clomipramine	DMINRKW	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Clomipramine.	Depression [6A70-6A7Z]	[9]
Trazodone	DMK1GBJ	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Trazodone.	Depression [6A70-6A7Z]	[9]
Amitriptyline	DMK7F9S	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Amitriptyline.	Depression [6A70-6A7Z]	[9]
Mirtazapine	DML53ZJ	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Mirtazapine.	Depression [6A70-6A7Z]	[9]
Protriptyline	DMNHTZI	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Protriptyline.	Depression [6A70-6A7Z]	[9]
Doxepin	DMPI98T	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Doxepin.	Depression [6A70-6A7Z]	[9]
Maprotiline	DMPWB7T	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Maprotiline.	Depression [6A70-6A7Z]	[9]
Venlafaxine	DMR6QH0	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Venlafaxine.	Depression [6A70-6A7Z]	[9]
Heme	DMGC287	Moderate	Increased risk of bleeding by the combination of Anagrelide and Heme.	Discovery agent [N.A.]	[25]
Apigenin	DMI3491	Minor	Increased risk of bleeding by the combination of Anagrelide and Apigenin.	Discovery agent [N.A.]	[26]
PMID28870136-Compound-48	DMPIM9L	Moderate	Decreased metabolism of Anagrelide caused by PMID28870136-Compound-48 mediated inhibition of CYP450 enzyme.	Discovery agent [N.A.]	[10]
PMID28870136-Compound-49	DMTUC9E	Moderate	Increased risk of bleeding by the combination of Anagrelide and PMID28870136-Compound-49.	Discovery agent [N.A.]	[9]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[9]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Deutetrabenazine.	Dystonic disorder [8A02]	[9]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Ingrezza.	Dystonic disorder [8A02]	[9]
Fenfluramine	DM0762O	Moderate	Increased risk of bleeding by the combination of Anagrelide and Fenfluramine.	Epilepsy/seizure [8A61-8A6Z]	[20]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Anagrelide caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[11]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Anagrelide caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[10]
Carbamazepine	DMZOLBI	Moderate	Increased metabolism of Anagrelide caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[10]
Suprofen	DMKXJZ7	Moderate	Increased risk of bleeding by the combination of Anagrelide and Suprofen.	Eye anterior segment structural developmental anomaly [LA11]	[19]
Mefenamic acid	DMK7HFI	Moderate	Increased risk of bleeding by the combination of Anagrelide and Mefenamic acid.	Female pelvic pain [GA34]	[19]
Solifenacin	DMG592Q	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Solifenacin.	Functional bladder disorder [GC50]	[9]
Pentamidine	DMHZJCG	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Pentamidine.	Fungal infection [1F29-1F2F]	[9]
Ketoconazole	DMPZI3Q	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Ketoconazole.	Fungal infection [1F29-1F2F]	[9]
Omeprazole	DM471KJ	Moderate	Increased metabolism of Anagrelide caused by Omeprazole mediated induction of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[10]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Anagrelide caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[15]
Cisapride	DMY7PED	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Cisapride.	Gastro-oesophageal reflux disease [DA22]	[9]
Sunitinib	DMCBJSR	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[9]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Anagrelide and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[11]
Carvedilol	DMHTEAO	Moderate	Decreased metabolism of Anagrelide caused by Carvedilol mediated inhibition of CYP450 enzyme.	Heart failure [BD10-BD1Z]	[10]
Isoniazid	DM5JVS3	Moderate	Decreased metabolism of Anagrelide caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[15]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Anagrelide caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[10]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[9]
Tipranavir	DM8HJX6	Major	Increased risk of bleeding by the combination of Anagrelide and Tipranavir.	Human immunodeficiency virus disease [1C60-1C62]	[27]
Efavirenz	DMC0GSJ	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[29]
Lopinavir	DMITQS0	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[10]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[9]
Verapamil	DMA7PEW	Moderate	Decreased metabolism of Anagrelide caused by Verapamil mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[15]
Pirfenidone	DM6VZFQ	Moderate	Decreased metabolism of Anagrelide caused by Pirfenidone mediated inhibition of CYP450 enzyme.	Idiopathic interstitial pneumonitis [CB03]	[11]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Anagrelide caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[15]
Meclofenamic acid	DM05FXR	Moderate	Increased risk of bleeding by the combination of Anagrelide and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[19]
Ramelteon	DM7IW9J	Moderate	Decreased metabolism of Anagrelide caused by Ramelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[30]
Melatonin	DMKWFBT	Moderate	Decreased metabolism of Anagrelide caused by Melatonin mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[10]
Tasimelteon	DMLOQ1V	Moderate	Decreased metabolism of Anagrelide caused by Tasimelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[31]
Zolpidem	DMWOSKJ	Moderate	Decreased metabolism of Anagrelide caused by Zolpidem mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[10]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Anagrelide and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[11]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Anagrelide and Phenolphthalein.	Irritable bowel syndrome [DD91]	[9]
Alosetron	DML2A03	Moderate	Decreased metabolism of Anagrelide caused by Alosetron mediated inhibition of CYP450 enzyme.	Irritable bowel syndrome [DD91]	[32]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Crizotinib.	Lung cancer [2C25]	[9]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Ceritinib.	Lung cancer [2C25]	[9]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Osimertinib.	Lung cancer [2C25]	[9]
Capmatinib	DMYCXKL	Moderate	Decreased metabolism of Anagrelide caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[15]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Selpercatinib.	Lung cancer [2C25]	[9]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Lumefantrine.	Malaria [1F40-1F45]	[10]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Halofantrine.	Malaria [1F40-1F45]	[33]
Chloroquine	DMSI5CB	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Chloroquine.	Malaria [1F40-1F45]	[34]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Hydroxychloroquine.	Malaria [1F40-1F45]	[34]
Quinine	DMSWYF5	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Quinine.	Malaria [1F40-1F45]	[9]
Primaquine	DMWQ16I	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Primaquine.	Malaria [1F40-1F45]	[9]
Mefloquine	DMWT905	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Mefloquine.	Malaria [1F40-1F45]	[9]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[9]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Anagrelide and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[35]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Anagrelide and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[36]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Anagrelide and Ibrutinib.	Mature B-cell lymphoma [2A85]	[37]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Anagrelide and Ponatinib.	Mature B-cell lymphoma [2A85]	[38]
LGX818	DMNQXV8	Major	Increased risk of prolong QT interval by the combination of Anagrelide and LGX818.	Melanoma [2C30]	[9]
Propranolol	DM79NTF	Moderate	Decreased metabolism of Anagrelide caused by Propranolol mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[10]
Riluzole	DMECBWN	Moderate	Decreased metabolism of Anagrelide caused by Riluzole mediated inhibition of CYP450 enzyme.	Motor neuron disease [8B60]	[10]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Panobinostat.	Multiple myeloma [2A83]	[39]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Anagrelide and Thalidomide.	Multiple myeloma [2A83]	[10]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Anagrelide and Siponimod.	Multiple sclerosis [8A40]	[10]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Anagrelide and Fingolimod.	Multiple sclerosis [8A40]	[9]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Anagrelide and Ozanimod.	Multiple sclerosis [8A40]	[40]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Romidepsin.	Mycosis fungoides [2B01]	[9]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Nilotinib.	Myeloproliferative neoplasm [2A20]	[9]
Dasatinib	DMJV2EK	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Dasatinib.	Myeloproliferative neoplasm [2A20]	[9]
Omacetaxine mepesuccinate	DMPU2WX	Major	Increased risk of bleeding by the combination of Anagrelide and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[18]
Prasugrel	DM7MT6E	Major	Increased risk of bleeding by the combination of Anagrelide and Prasugrel.	Myocardial infarction [BA41-BA43]	[11]
Vorapaxar	DMA16BR	Major	Increased risk of bleeding by the combination of Anagrelide and Vorapaxar.	Myocardial infarction [BA41-BA43]	[41]
Tirofiban	DMQG17S	Major	Increased risk of bleeding by the combination of Anagrelide and Tirofiban.	Myocardial infarction [BA41-BA43]	[42]
Droperidol	DM0DXA8	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Droperidol.	Nausea/vomiting [MD90]	[9]
Prochlorperazine	DM53SRA	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Prochlorperazine.	Nausea/vomiting [MD90]	[9]
Promethazine	DM6I5GR	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Promethazine.	Nausea/vomiting [MD90]	[9]
Palonosetron	DMBHMOX	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Palonosetron.	Nausea/vomiting [MD90]	[9]
Granisetron	DMIUW25	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Granisetron.	Nausea/vomiting [MD90]	[9]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Dolasetron.	Nausea/vomiting [MD90]	[9]
Ondansetron	DMOTQ1I	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Ondansetron.	Nausea/vomiting [MD90]	[9]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Entrectinib.	Non-small cell lung cancer [2C25]	[9]
Sibutramine	DMFJTDI	Moderate	Increased risk of bleeding by the combination of Anagrelide and Sibutramine.	Obesity [5B80-5B81]	[20]
Dexfenfluramine	DMJ7YDS	Moderate	Increased risk of bleeding by the combination of Anagrelide and Dexfenfluramine.	Obesity [5B80-5B81]	[20]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Levomethadyl Acetate.	Opioid use disorder [6C43]	[11]
Lofexidine	DM1WXA6	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Lofexidine.	Opioid use disorder [6C43]	[9]
Rofecoxib	DM3P5DA	Moderate	Decreased metabolism of Anagrelide caused by Rofecoxib mediated inhibition of CYP450 enzyme.	Osteoarthritis [FA00-FA05]	[15]
Diclofenac	DMPIHLS	Moderate	Increased risk of bleeding by the combination of Anagrelide and Diclofenac.	Osteoarthritis [FA00-FA05]	[19]
Nepafenac	DMYK490	Moderate	Increased risk of bleeding by the combination of Anagrelide and Nepafenac.	Osteoarthritis [FA00-FA05]	[19]
Naproxen	DMZ5RGV	Moderate	Increased risk of bleeding by the combination of Anagrelide and Naproxen.	Osteoarthritis [FA00-FA05]	[19]
Olaparib	DM8QB1D	Moderate	Increased metabolism of Anagrelide caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[10]
Rucaparib	DM9PVX8	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Rucaparib.	Ovarian cancer [2C73]	[9]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Anagrelide and MK-4827.	Ovarian cancer [2C73]	[11]
Dextropropoxyphene	DM23HCX	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Dextropropoxyphene.	Pain [MG30-MG3Z]	[10]
Etodolac	DM6WJO9	Moderate	Increased risk of bleeding by the combination of Anagrelide and Etodolac.	Pain [MG30-MG3Z]	[19]
Diflunisal	DM7EN8I	Moderate	Increased risk of bleeding by the combination of Anagrelide and Diflunisal.	Pain [MG30-MG3Z]	[19]
Ibuprofen	DM8VCBE	Moderate	Increased risk of bleeding by the combination of Anagrelide and Ibuprofen.	Pain [MG30-MG3Z]	[19]
Nabumetone	DMAT2XH	Moderate	Increased risk of bleeding by the combination of Anagrelide and Nabumetone.	Pain [MG30-MG3Z]	[19]
Buprenorphine	DMPRI8G	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Buprenorphine.	Pain [MG30-MG3Z]	[9]
Piroxicam	DMTK234	Moderate	Increased risk of bleeding by the combination of Anagrelide and Piroxicam.	Pain [MG30-MG3Z]	[19]
Acetaminophen	DMUIE76	Moderate	Decreased metabolism of Anagrelide caused by Acetaminophen mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[10]
Thiabendazole	DM7YCK3	Moderate	Decreased metabolism of Anagrelide caused by Thiabendazole mediated inhibition of CYP450 enzyme.	Parasitic worm infestation [1F90]	[15]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Triclabendazole.	Parasitic worm infestation [1F90]	[9]
Albendazole	DMYZ57N	Moderate	Decreased metabolism of Anagrelide caused by Albendazole mediated inhibition of CYP450 enzyme.	Parasitic worm infestation [1F90]	[10]
Rasagiline	DM3WKQ4	Moderate	Decreased metabolism of Anagrelide caused by Rasagiline mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[10]
Ropinirole	DMA6S1D	Moderate	Decreased metabolism of Anagrelide caused by Ropinirole mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[43]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Pimavanserin.	Parkinsonism [8A00]	[9]
Apomorphine	DMX38HQ	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Apomorphine.	Parkinsonism [8A00]	[9]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Anagrelide caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[44]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Anagrelide and Famotidine.	Peptic ulcer [DA61]	[10]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[45]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Lefamulin.	Pneumonia [CA40]	[9]
Ketorolac	DMI4EL5	Moderate	Increased risk of bleeding by the combination of Anagrelide and Ketorolac.	Postoperative inflammation [1A00-CA43]	[19]
Bromfenac	DMKB79O	Moderate	Increased risk of bleeding by the combination of Anagrelide and Bromfenac.	Postoperative inflammation [1A00-CA43]	[19]
Ritodrine	DM4V6RL	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Ritodrine.	Preterm labour/delivery [JB00]	[13]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Degarelix.	Prostate cancer [2C82]	[9]
ABIRATERONE	DM8V75C	Major	Increased risk of prolong QT interval by the combination of Anagrelide and ABIRATERONE.	Prostate cancer [2C82]	[9]
Nilutamide	DMFN07X	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Nilutamide.	Prostate cancer [2C82]	[9]
Enzalutamide	DMGL19D	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Enzalutamide.	Prostate cancer [2C82]	[9]
Flutamide	DMK0O7U	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Flutamide.	Prostate cancer [2C82]	[9]
Bicalutamide	DMZMSPF	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Bicalutamide.	Prostate cancer [2C82]	[9]
Alfuzosin	DMZVMKF	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Alfuzosin.	Prostate hyperplasia [GA90]	[9]
Levomepromazine	DMIKFEL	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Levomepromazine.	Psychotic disorder [6A20-6A25]	[9]
Fluphenazine	DMIT8LX	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Fluphenazine.	Psychotic disorder [6A20-6A25]	[9]
Triflupromazine	DMKFQJP	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Triflupromazine.	Psychotic disorder [6A20-6A25]	[9]
Treprostinil	DMTIQF3	Moderate	Increased risk of bleeding by the combination of Anagrelide and Treprostinil.	Pulmonary hypertension [BB01]	[46]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Anagrelide and Epoprostenol.	Pulmonary hypertension [BB01]	[46]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Anagrelide and Iloprost.	Pulmonary hypertension [BB01]	[46]
Axitinib	DMGVH6N	Moderate	Decreased metabolism of Anagrelide caused by Axitinib mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[10]
Sorafenib	DMS8IFC	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Sorafenib.	Renal cell carcinoma [2C90]	[9]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[47]
Meloxicam	DM2AR7L	Moderate	Increased risk of bleeding by the combination of Anagrelide and Meloxicam.	Rheumatoid arthritis [FA20]	[19]
Sulindac	DM2QHZU	Moderate	Increased risk of bleeding by the combination of Anagrelide and Sulindac.	Rheumatoid arthritis [FA20]	[19]
Oxaprozin	DM9UB0P	Moderate	Increased risk of bleeding by the combination of Anagrelide and Oxaprozin.	Rheumatoid arthritis [FA20]	[19]
Flurbiprofen	DMGN4BY	Moderate	Increased risk of bleeding by the combination of Anagrelide and Flurbiprofen.	Rheumatoid arthritis [FA20]	[19]
Fenoprofen	DML5VQ0	Moderate	Increased risk of bleeding by the combination of Anagrelide and Fenoprofen.	Rheumatoid arthritis [FA20]	[19]
Indomethacin	DMSC4A7	Moderate	Increased risk of bleeding by the combination of Anagrelide and Indomethacin.	Rheumatoid arthritis [FA20]	[19]
Tolmetin	DMWUIJE	Moderate	Increased risk of bleeding by the combination of Anagrelide and Tolmetin.	Rheumatoid arthritis [FA20]	[19]
Quetiapine	DM1N62C	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Quetiapine.	Schizophrenia [6A20]	[9]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Mesoridazine.	Schizophrenia [6A20]	[9]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Thioridazine.	Schizophrenia [6A20]	[9]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Anagrelide and Aripiprazole.	Schizophrenia [6A20]	[10]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Iloperidone.	Schizophrenia [6A20]	[9]
Paliperidone	DM7NPJS	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Paliperidone.	Schizophrenia [6A20]	[9]
Haloperidol	DM96SE0	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Haloperidol.	Schizophrenia [6A20]	[9]
Perphenazine	DMA4MRX	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Perphenazine.	Schizophrenia [6A20]	[9]
Chlorpromazine	DMBGZI3	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Chlorpromazine.	Schizophrenia [6A20]	[9]
Clozapine	DMFC71L	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Clozapine.	Schizophrenia [6A20]	[9]
Trifluoperazine	DMKBYWI	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Trifluoperazine.	Schizophrenia [6A20]	[9]
Risperidone	DMN6DXL	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Risperidone.	Schizophrenia [6A20]	[9]
Olanzapine	DMPFN6Y	Moderate	Decreased metabolism of Anagrelide caused by Olanzapine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[48]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Amisulpride.	Schizophrenia [6A20]	[9]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Asenapine.	Schizophrenia [6A20]	[9]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Pimozide.	Schizophrenia [6A20]	[11]
Vardenafil	DMTBGW8	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Vardenafil.	Sexual dysfunction [HA00-HA01]	[9]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Anagrelide and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[9]
Epirubicin	DMPDW6T	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[9]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[9]
Triptorelin	DMTK4LS	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[9]
Doxorubicin	DMVP5YE	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[9]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Pitolisant.	Somnolence [MG42]	[9]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[9]
Ibutilide	DMKXY2R	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Ibutilide.	Supraventricular tachyarrhythmia [BC81]	[9]
Adenosine	DMM2NSK	Major	Increased risk of ventricular arrhythmias by the combination of Anagrelide and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[49]
Caplacizumab	DMPUKA7	Major	Increased risk of bleeding by the combination of Anagrelide and Caplacizumab.	Thrombocytopenia [3B64]	[10]
Apixaban	DM89JLN	Major	Increased risk of bleeding by the combination of Anagrelide and Apixaban.	Thrombosis [DB61-GB90]	[11]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Anagrelide and Brilinta.	Thrombosis [DB61-GB90]	[11]
Argatroban	DMFI46A	Major	Increased risk of bleeding by the combination of Anagrelide and Argatroban.	Thrombosis [DB61-GB90]	[50]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Lenvatinib.	Thyroid cancer [2D10]	[9]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Cabozantinib.	Thyroid cancer [2D10]	[9]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Papaverine.	Tonus and reflex abnormality [MB47]	[51]
Tizanidine	DMR2IQ4	Major	Decreased metabolism of Anagrelide caused by Tizanidine mediated inhibition of CYP450 enzyme.	Tonus and reflex abnormality [MB47]	[52]
Tacrolimus	DMZ7XNQ	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Tacrolimus.	Transplant rejection [NE84]	[9]
Nalidixic acid	DMRM0JV	Moderate	Decreased metabolism of Anagrelide caused by Nalidixic acid mediated inhibition of CYP450 enzyme.	Urinary tract infection [GC08]	[15]
Enoxacin	DMYTE6L	Moderate	Decreased metabolism of Anagrelide caused by Enoxacin mediated inhibition of CYP450 enzyme.	Urinary tract infection [GC08]	[15]
Astemizole	DM2HN6Q	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[9]
Trimeprazine	DMEMV9D	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[10]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Anagrelide and Betrixaban.	Venous thromboembolism [BD72]	[53]
Disopyramide	DM5SYZP	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Disopyramide.	Ventricular tachyarrhythmia [BC71]	[9]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Procainamide.	Ventricular tachyarrhythmia [BC71]	[9]
Propafenone	DMPIBJK	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Propafenone.	Ventricular tachyarrhythmia [BC71]	[9]
Flecainide	DMSQDLE	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Flecainide.	Ventricular tachyarrhythmia [BC71]	[9]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Anagrelide and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[9]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Potassium hydroxide	E00233	14797	Alkalizing agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Anagrelide 0.5 mg capsule	0.5 mg	Oral Capsule	Oral
Anagrelide 1 mg capsule	1 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7114).
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] FDA Approved Drug Products: Agrylin (anagrelide) oral capsules
• [4] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [5] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [6] Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45.
• [7] Open-label, dose-titration and continuation study to assess efficacy, safety, and pharmacokinetics of anagrelide in treatment-nae Japanese patients with essential thrombocythemia. Int J Hematol. 2013 Mar;97(3):360-8.
• [8] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [9] Canadian Pharmacists Association.
• [10] Cerner Multum, Inc. "Australian Product Information.".
• [11] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [12] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [13] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [14] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
• [15] Product Information. Agrylin (anagrelide). Roberts Pharmaceutical Corporation, Eatontown, NJ.
• [16] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [17] Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
• [18] Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
• [19] Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
• [20] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
• [21] Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
• [22] Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
• [23] Price AJ, Frcpath DO "Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?" Ann R Coll Surg Engl 77 (1995): 395. [PMID: 7486773]
• [24] Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
• [25] Product Information. Panhematin (hemin). Recordati Rare Diseases Inc, Lebanon, NJ.
• [26] Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
• [27] Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
• [28] Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
• [29] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [30] Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
• [31] Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
• [32] Product Information. Lotronex (alosetron). Glaxo Wellcome, Research Triangle Park, NC.
• [33] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [34] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [35] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [36] Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [37] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [38] Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
• [39] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [40] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [41] Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
• [42] Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
• [43] Product Information. Noroxin (norfloxacin). Merck & Co, Inc, West Point, PA.
• [44] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [45] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [46] Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
• [47] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [48] Albers LJ, Ozdemir V, Marder SR, et al. "Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy." J Clin Psychopharmacol 25 (2005): 170-174. [PMID: 15738749]
• [49] Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
• [50] Product Information. Acova (argatroban) SmithKline Beecham, Philadelphia, PA.
• [51] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
• [52] Granfors MT, Backman JT, Laitila J, Neuvonen PJ "Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro." Br J Clin Pharmacol 57 (2004): 349-53. [PMID: 14998432]
• [53] Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.